Trial · NCT03125902
Results by group54
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 54
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status | Placebo and Paclitaxel | 5.72 | 95% Confidence Interval 5.39 to 7.20 | Months | |
| Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status | Atezolizumab and Paclitaxel | 5.95 | 95% Confidence Interval 5.62 to 7.43 | Months | |
| Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | Placebo and Paclitaxel | 5.55 | 95% Confidence Interval 5.36 to 6.51 | Months | |
| Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population | Atezolizumab and Paclitaxel | 5.68 | 95% Confidence Interval 5.42 to 7.16 | Months | |
| Overall Survival (OS) in the PD-L1-Positive Subpopulation | Placebo and Paclitaxel | 28.29 | 95% Confidence Interval 19.06 to NA | Months | |
| Overall Survival (OS) in the PD-L1-Positive Subpopulation | Atezolizumab and Paclitaxel | 22.05 | 95% Confidence Interval 19.19 to 30.52 | Months | |
| Overall Survival (OS) in the ITT Population | Placebo and Paclitaxel | 22.80 | 95% Confidence Interval 17.08 to 28.29 | Months | |
| Overall Survival (OS) in the ITT Population | Atezolizumab and Paclitaxel | 19.19 | 95% Confidence Interval 16.59 to 22.05 | Months | |
| Percentage of Participants Who Are Alive at 12 and 18 Months | Placebo and Paclitaxel | 12 months | 73.47 | 95% Confidence Interval 67.44 to 79.49 | Percentage of Participants |
| Percentage of Participants Who Are Alive at 12 and 18 Months | Atezolizumab and Paclitaxel | 12 months | 68.86 | 95% Confidence Interval 64.37 to 73.34 | Percentage of Participants |
| Percentage of Participants Who Are Alive at 12 and 18 Months | Placebo and Paclitaxel | 18 months | 56.18 | 95% Confidence Interval 48.94 to 63.42 | Percentage of Participants |
| Percentage of Participants Who Are Alive at 12 and 18 Months | Atezolizumab and Paclitaxel | 18 months | 52.32 | 95% Confidence Interval 47.15 to 57.48 | Percentage of Participants |
| Time to Deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL) in the PRO Evaluable Population | Placebo and Paclitaxel | 17.35 | 95% Confidence Interval 9.23 to NA | Months | |
| Time to Deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL) in the PRO Evaluable Population | Atezolizumab and Paclitaxel | 28.68 | 95% Confidence Interval 11.99 to NA | Months | |
| Percentage of Participants Who Are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1 | Placebo and Paclitaxel | 16.22 | 95% Confidence Interval 10.18 to 22.26 | Percentage of Participants | |
| Percentage of Participants Who Are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1 | Atezolizumab and Paclitaxel | 21.63 | 95% Confidence Interval 16.74 to 26.51 | Percentage of Participants | |
| Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Confirmed, Investigator-Assessed ) | Placebo and Paclitaxel | 40.6 | 95% Confidence Interval 30.93 to 50.82 | Percentage of Participants | |
| Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Confirmed, Investigator-Assessed ) | Atezolizumab and Paclitaxel | 49.2 | 95% Confidence Interval 41.92 to 56.53 | Percentage of Participants | |
| Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Unconfirmed, Investigator-Assessed) | Placebo and Paclitaxel | 55.4 | 95% Confidence Interval 45.22 to 65.34 | Percentage of Participants | |
| Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Unconfirmed, Investigator-Assessed) | Atezolizumab and Paclitaxel | 63.4 | 95% Confidence Interval 56.09 to 70.19 | Percentage of Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03125902/results